Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and leukemia group B

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1698-1704

  Vokes, Everett E ^a   Herndon II, James E ^a   Kelley, Michael J ^a   Cicchetti, M Giulia ^a   Ramnath, Nithya ^a   Neill, Harvey ^a   Atkins, James N ^a   Watson, Dorothy M ^a   Akerley, Wallace ^a   Green, Mark R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONSET AGE; PNEUMONIA; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 34248651350     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.3569     Document Type: Article

References (36)

1. Ginsberg R, Vokes EE, Rosenzweig K: Non-small-cell lung cancer, in DeVita JV, Hellman, S, Rosenberg, SA (ed): Cancer-Principles and Practice of Oncology (ed 7). Philadelphia, PA, Lippencott, Williams, and Wilkins, 2004
2. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355:479-485, 2000 [Erratum: Lancet 355:1280, 2000]
3. Gordon GS, Vokes EE: Chemoradiation for locally advanced, unresectable NSCLC: New standard of care, emerging strategies. Oncology (Huntingt) 13:1075-1088; discussion, 1088, 1091-1094, 1999
4. Komaki R, Scott CB, Byhardt R, et al: Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1,547 patients on four radiation therapy oncology group (RTOG) studies in inoperable non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 42:263-267, 1998
5. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350:379-392, 2004
6. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
7. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
8. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
9. Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000
10. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
11. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
12. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
13. Curran WJ, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
14. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small-cell lung cancer: A randomized study. Lung Cancer 46:87-98, 2004
15. Pierre F, Maurice P, Gilles R, et al: A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 20:312a, 2001 (abstr 1246)
16. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005
17. Vokes EE: Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol 23:5853-5855, 2005
18. Clamon G, Herndon J, Cooper R, et al: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11, 1999
19. Gervais R, Ducolone A, Lechevalier T, et al: Conventional radiation with daily carboplatin compared with RT alone after induction chemotherapy: Final results of a randomized phase III trial in stage III unresectable non-small-cell lung cancer. Study CRT/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 23:625s, 2005 (abstr 7016)
20. Vokes EE, Herndon JE II, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002
21. Akerley W, Herndon JE Jr, Lyss AP, et al: Induction paclitaxel/ carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study CALGB 9534. Clin Lung Cancer 7:47-53, 2005
22. Choy H, Akerley W, Safran H, et al: Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998
23. Choy H, Safran H, Akerley W, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Clin Cancer Res 4:1931-1936, 1998
24. Choy H, Devore RF III, Hande KR, et al: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network Study. Int J Radiat Oncol Biol Phys 47:931-937, 2000
25. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005
26. Calvert AH, Boddy A, Bailey NP, et al: Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98; discussion 99-100, 1995
27. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
28. Albain KS, Crowley JJ, Turrisi AT III, et al: Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460, 2002
29. Komaki R, Scott C, Ettinger D, et al: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149-155, 1997
30. Kelly K, Gaspar LE, Chansky K, et al: Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small-cell lung cancer. J Clin Oncol 23:634s, 2005 (abstr 7058)
31. Seiwert TY, Connell PP, Mauer AM, et al: A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small-cell lung or esophageal cancer. J Clin Oncol 23:16s, 2005 (abstr 7062)
32. Ready N, Herndon J, Vokes EE, et al: Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small-cell lung cancer (NSCLC): A CALGB stratified phase II trial. J Clin Oncol 22:14S, 2004 (abstr 7078)
33. Merchant J, Kim K, Mehta M, et al: Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non-small-cell lung cancer. Clin Lung Ca 2:48-52, 2000
34. Mauer A, Haraf D, Hoffman PC, et al: A phase I study of OSI-774 in combination with chemoradiation (CRT) for unresectable locally advanced non-small-cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 22:651, 2003
35. Rischin D, Burnmeister B, Mitchell P, et al: Phase I trial of geftinib (ZD1839) in combination with concurrent carboplatin, paclitaxel, and radiation therapy in patients with stage III non-small-cell lung cancer. J Clin Oncol 22:14S, 2004 (abstr 7077)
36. Bonner JA, Giralt J, Harari PM, et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high-dose radiation therapy with or without cetuximab. ASCO Annual Meeting Proceedings. New Orleans, LA, 2004, pp 489s (abstr 5507)